Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 56, 2021 - Issue 9
Submit an article Journal homepage
660
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases

Mohamed Attauabia Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark;b Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark;c Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Herlev, DenmarkCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0323-7030View further author information
ORCID Icon,
Camilla Höglundd Department of Medicine, Section of Gastroenterology, OUH Svendborg Hospital, Odense, DenmarkView further author information
,
Janne Fassove Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, DenmarkView further author information
,
Kenneth Bo Pedersenf Department of Medical Gastroenterology, Hospital of South West Denmark, Esbjerg, DenmarkView further author information
,
Heidi Bansholm Hanseng Department of Gastroenterology, North Zealand University Hospital, Frederikssund, DenmarkView further author information
,
Signe Wildth Department of Medicine, Division of Gastroenterology, Zealand University Hospital, Koege, DenmarkView further author information
,
Michael Dam Jenseni Department of Internal Medicine, Section of Gastroenterology, Lillebaelt Hospital, Vejle, DenmarkView further author information
,
Anders Neumannj Department of Internal Medicine, Regional Hospital Viborg, Viborg, DenmarkView further author information
,
Cecilie Lindj Department of Internal Medicine, Regional Hospital Viborg, Viborg, DenmarkView further author information
,
Henrik Albaek Jacobsenk Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, DenmarkView further author information
,
Ana-Maria Popal Department of Medicine, Nykoebing Falster Hospital, Nykoebing Falster, DenmarkView further author information
,
Jens Kjeldsenm Department of Medical Gastroenterology, OUH Odense University Hospital, Odense, DenmarkView further author information
,
Natalia Pedersenn Department of Gastroenterology, Slagelse Hospital, Slagelse, DenmarkView further author information
,
Akbar Molazahio Department of Internal Medicine, Holbaek Hospital, Holbaek, DenmarkView further author information
,
Kent Haderslevp Department of Gastroenterology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkView further author information
,
Claus Aalykked Department of Medicine, Section of Gastroenterology, OUH Svendborg Hospital, Odense, DenmarkView further author information
,
Torben Knudsenf Department of Medical Gastroenterology, Hospital of South West Denmark, Esbjerg, DenmarkView further author information
,
Wojciech Cebulal Department of Medicine, Nykoebing Falster Hospital, Nykoebing Falster, DenmarkView further author information
,
Pia Munkholmg Department of Gastroenterology, North Zealand University Hospital, Frederikssund, DenmarkORCID Iconhttps://orcid.org/0000-0002-7263-1122View further author information
ORCID Icon,
Flemming Bendtsena Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark;b Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Hvidovre, DenmarkORCID Iconhttps://orcid.org/0000-0002-8419-2104View further author information
ORCID Icon,
Jakob Benedict Seidelinc Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Herlev, DenmarkORCID Iconhttps://orcid.org/0000-0003-3230-7966View further author information
ORCID Icon &
Johan Burischa Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark;b Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Hvidovre, DenmarkORCID Iconhttps://orcid.org/0000-0002-3312-5139View further author information
ORCID Icon show all
Pages 1040-1048 | Received 27 Apr 2021, Accepted 17 Jun 2021, Published online: 05 Jul 2021

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Antonio Tursi, Giammarco Mocci, Angelo Del Gaudio & Alfredo Papa. (2024) Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies. Expert Opinion on Biological Therapy 24:3, pages 171-189.
Read now
Laura Neurath, Ferdinando D’Amico & Silvio Danese. (2023) Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. Expert Opinion on Emerging Drugs 28:1, pages 27-42.
Read now

Articles from other publishers (10)

Dushyant Singh Dahiya, Saurabh Chandan, Jay Bapaye, Babu P. Mohan, Daryl Ramai, Lena L. Kassab, Ojasvini C. Chandan, Parambir S. Dulai & Gursimran S. Kochhar. (2024) Safety and Effectiveness of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 58:4, pages 378-388.
Crossref
Adriana Zanoni Dotti, Daniela Oliveira Magro, Eduardo Garcia Vilela, Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Flavio Steinwurz, Marjorie Argollo, Nayara Salgado Carvalho, Jose Miguel Luz Parente, Murilo Moura Lima, Rogério Serafim Parra, Ramir Luan Perin, Cristina Flores, Eloá Marussi Morsoletto, Sandro da Costa Ferreira, Juliano Coelho Ludvig, Roberto Luiz Kaiser Junior, Mikaell Alexandre Gouvea Faria, Guilherme Mattioli Nicollelli, Adriana Ribas Andrade, Natalia Sousa Freitas Queiroz & Paulo Gustavo Kotze. (2023) Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study. Crohn's & Colitis 360 5:4.
Crossref
Fabio Salvatore Macaluso, Marco Ventimiglia & Ambrogio Orlando. (2023) Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies. Journal of Crohn's and Colitis 17:8, pages 1217-1227.
Crossref
Bente Mertz Nørgård, Floor Dijkstra Zegers, Torben Knudsen, Jens Kjeldsen, Ken Lund, Jacob Broder Brodersen & Jan Nielsen. (2023) Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries—A nationwide cohort study. Alimentary Pharmacology & Therapeutics 58:1, pages 48-59.
Crossref
Walter Fries, Giorgio Basile, Federica Bellone, Giuseppe Costantino & Anna Viola. (2023) Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease. Cells 12:13, pages 1722.
Crossref
Ahmad Albshesh, Lian Bannon, Tali Sharar Fischler, Marie Truyens, Stephan Vavricka, Katja Tepes, Daniela Pugliese, Edoardo Savarino, Eran Zittan, David Drobne, Xavier Roblin, Ariella Bar-Gil Shitrit, Alessandro Armuzzi, Triana Lobaton, Nitsan Maharshak, Henit Yanai, Shomron Ben-Horin & Uri Kopylov. (2023) Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine 12:7, pages 2503.
Crossref
Kazuhiko Uchiyama, Tomohisa Takagi, Katsura Mizushima, Yasuko Hirai, Kohei Asaeda, Takeshi Sugaya, Mariko Kajiwara-Kubota, Saori Kashiwagi, Yuki Minagawa, Yuma Hotta, Makoto Tanaka, Ken Inoue, Kazuhiro Katada, Kazuhiro Kamada, Takeshi Ishikawa, Hiroaki Yasuda, Hideyuki Konishi, Mitsuo Kishimoto, Yuji Naito & Yoshito Itoh. (2022) Mucosal Addressin Cell Adhesion Molecule 1 Expression Reflects Mucosal Inflammation and Subsequent Relapse in Patients with Ulcerative Colitis. Journal of Crohn's and Colitis.
Crossref
Mohamed Attauabi, Gorm Roager Madsen, Flemming Bendtsen, Jakob Benedict Seidelin & Johan Burisch. (2022) Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis. Digestive and Liver Disease 54:9, pages 1168-1178.
Crossref
Walter Fries, Maria Giulia Demarzo, Giuseppe Navarra & Anna Viola. (2022) Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks?. Drugs & Aging 39:6, pages 441-452.
Crossref
. (2022) Vedolizumab. Reactions Weekly 1887:1, pages 669-669.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.